文献速递慢性肾脏病急性肾损伤

糖尿病患者的长期访视间糖化血红蛋白变异性与肾脏相关结局

Long-term Visit-to-Visit Variability in Hemoglobin A1c and Kidney-Related Outcomes in Persons With Diabetes.
PubMed 文献 · Am J Kidney Dis · 2023-05-13

在瑞典斯德哥尔摩93,598例常规诊疗的成人糖尿病患者中,评估长期访视间HbA1c变异性(HbA1c变异性评分HVS)与肾脏不良结局的关联。以HVS 0-20%为参照,HVS 81%-100%者CKD进展校正HR 1.6(95%CI 1.47-1.74)、AKI 1.23(1.16-1.3)、白蛋白尿恶化1.28(1.21-1.36)。结论认为较高的长期访视间HbA1c变异性与CKD进展、AKI及白蛋白尿恶化风险持续相关。

要点

  • HVS 81%-100%者CKD进展校正HR 1.6(95%CI 1.47-1.74),高于HVS 0-20%参照组。
  • HVS 81%-100%者AKI校正HR 1.23(95%CI 1.16-1.3),白蛋白尿恶化校正HR 1.28(1.21-1.36)。
  • 结果在糖尿病亚型、基线eGFR及白蛋白尿分类亚组、时变分析和敏感性分析中一致。

核心结论

  • 较高的长期访视间HbA1c变异性与CKD进展、AKI及白蛋白尿恶化风险持续相关。

研究设计与样本

  • 观察性研究,纳入瑞典斯德哥尔摩93,598例接受常规诊疗的成人糖尿病患者。
  • 暴露为基线和时变HbA1c变异性评分(HVS,3年窗口内HbA1c测量值变化>0.5%[5.5mmol/mol]的百分比),分为0-20%、21%-40%、41%-60%、61%-80%、81%-100%五类,以0-20%为参照组。
  • 采用多变量Cox比例风险回归分析。

主要发现

  • 与HVS 0-20%者相比,任何变异性升高均与肾脏不良结局风险升高相关,且独立于平均HbA1c。
  • 基线HVS 81%-100%者CKD进展校正HR 1.6(95%CI 1.47-1.74),AKI校正HR 1.23(95%CI 1.16-1.3),白蛋白尿恶化校正HR 1.28(95%CI 1.21-1.36)。
  • 结果在糖尿病亚型、基线eGFR或白蛋白尿分类亚组、时变分析以及纳入时间加权平均HbA1c或替代变异性指标的敏感性分析中一致。

局限性

  • 观察性研究。
  • 理赔数据存在局限性。
  • 缺乏饮食、体重指数、用药变化及糖尿病病程信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: To characterize associations between long-term visit-to-visit variability of hemoglobin A1c (HbA1c) and risk of adverse kidney outcomes in patients with diabetes. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 93,598 adults with diabetes undergoing routine care in Stockholm, Sweden. EXPOSURES AND PREDICTORS: Categories of baseline and time-varying HbA1c variability score (HVS, the percentage of total HbA1c measures that vary by>0.5% [5.5mmol/mol] during a 3-year window): 0-20%, 21%-40%, 41%-60%, 61%-80%, and 81%-100%, with 0-20% as the reference group. OUTCOME: Chronic kidney disease (CKD) progression (composite of>50% estimated glomerular filtration rate [eGFR] decline and kidney failure), acute kidney disease (AKI by clinical diagnosis or transient creatinine elevations according to KDIGO criteria), and worsening of albuminuria. ANALYTICAL APPROACH: Multivariable Cox proportional hazards regression. RESULTS: Compared with persons showing low HbA1c variability (HVS 0-20%), any increase in variability was associated with a higher risk of adverse kidney outcomes beyond mean HbA1c. For example, for patients with a baseline HbA1c variability of 81%-100%, the adjusted HR was 1.6 (95% CI, 1.47-1.74) for CKD progression, 1.23 [1.16-1.3] for AKI, and 1.28 [1.21-1.36] for worsening of albuminuria. The results were consistent across subgroups (diabetes subtypes, baseline eGFR, or albuminuria categories), in time-varying analyses and in sensitivity analyses including time-weighted average HbA1c or alternative metrics of variability. LIMITATIONS: Observational study, limitations of claims data, lack of information on diet, body mass index, medication changes, and diabetes duration. CONCLUSIONS: Higher long-term visit-to-visit HbA1c variability is consistently associated with the risks of CKD progression, AKI, and worsening of albuminuria. PLAIN-LANGUAGE SUMMARY: The evidence for current guideline recommendations derives from clinical trials that focus on a single HbA1c as the definitive measure of efficacy of an intervention. However, long-term visit-to-visit fluctuations of HbA1c may provide additional value in the prediction of future kidney complications. We evaluated the long-term fluctuations in glycemic control in almost 100,000 persons with diabetes undergoing routine care in Stockholm, Sweden. We observed that higher long-term HbA1c fluctuation is consistently associated with the risks of chronic kidney disease progression, worsening of albuminuria and acute kidney injury. This finding supports a role for long-term glycemic variability in the development of kidney complications and illustrates the potential usefulness of this metric for risk stratification at the bedside beyond a single HbA1c test.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Xu Y, Dong S, Fu EL, et al. Long-term Visit-to-Visit Variability in Hemoglobin A1c and Kidney-Related Outcomes in Persons With Diabetes. Am J Kidney Dis. 2023. PMID: 37182597. doi:10.1053/j.ajkd.2023.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。